BioAge Labs, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOA research report →
Companybioagelabs.com
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging.
- CEO
- Kristen Fortney
- IPO
- 2024
- Employees
- 62
- HQ
- Emeryville, CA, US
Price Chart
Valuation
- Market Cap
- $606.54M
- P/E
- -7.61
- P/S
- 58.80
- P/B
- 1.81
- EV/EBITDA
- -3.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.39%
- Op Margin
- -985.93%
- Net Margin
- -871.75%
- ROE
- -29.40%
- ROIC
- -26.51%
Growth & Income
- Revenue
- $8.99M · 0.00%
- Net Income
- $-80,605,000 · -13.35%
- EPS
- $-2.24 · 66.21%
- Op Income
- $-92,780,000
- FCF YoY
- -58.70%
Performance & Tape
- 52W High
- $24.00
- 52W Low
- $3.79
- 50D MA
- $17.90
- 200D MA
- $12.67
- Beta
- 1.00
- Avg Volume
- 474.55K
Get TickerSpark's AI analysis on BIOA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 23, 26 | GOLDSTEIN DOV A MD | other | 3,542 |
| Apr 23, 26 | GOLDSTEIN DOV A MD | other | 3,542 |
| Apr 1, 26 | RUBIN PAUL D | other | 3,383 |
| Apr 1, 26 | RUBIN PAUL D | other | 5,437 |
| Apr 1, 26 | RUBIN PAUL D | sell | 8,820 |
| Apr 1, 26 | RUBIN PAUL D | other | 5,437 |
| Apr 1, 26 | RUBIN PAUL D | other | 3,383 |
| Mar 2, 26 | RUBIN PAUL D | other | 2,000 |
| Mar 2, 26 | RUBIN PAUL D | other | 5,433 |
| Mar 2, 26 | RUBIN PAUL D | other | 5,433 |
Our BIOA Coverage
We haven't published any research on BIOA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BIOA Report →